Corvus Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Corvus Pharmaceuticals, Inc. on April 21, 2023. The report addresses a specific regulatory event regarding the company's listing status on the Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance and listing compliance event rather than financial performance.
Material Changes
The primary material change reported is the resolution of a Nasdaq listing deficiency. Previously, on October 25, 2022, the company received notice that its common stock failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days. The company was granted a 180-day compliance period ending April 24, 2023.
Outlook and Management Commentary
On April 21, 2023, the Nasdaq Listing Qualifications Department notified the company that it had regained compliance. The closing bid price of the common stock was at least $1.00 per share for 10 consecutive business days between April 6, 2023, and April 20, 2023. Consequently, the matter regarding the Minimum Bid Price Requirement is now closed.
Investor Verification Checklist
- Verify the current trading price of Corvus Pharmaceuticals (CRVS) to ensure it remains above the $1.00 threshold.
- Confirm the company's continued good standing on the Nasdaq Global Market.
- Review subsequent filings for any new compliance notices or financial updates, as this 8-K contains no financial data.